18889881171
Kalkine 0
countryflagUS

AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%

Achieve Life Sciences Inc

Healthcare US ACHV

1.99USD
-0.12(5.69%)

Last update at 2025-04-17T20:00:00Z

Day Range

1.952.13
LowHigh

52 Week Range

3.105.59
LowHigh

Fundamentals

  • Previous Close 2.11
  • Market Cap156.82M
  • Volume260145
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-31.03700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -42.35000M -33.15200M -14.73000M -16.39500M -12.68700M
Minority interest - - - - -
Net income -41.87500M -32.90200M -14.66100M -16.14100M -12.68700M
Selling general administrative 10.72M 9.13M 7.87M 6.85M 6.95M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.24M 0.25M 0.26M 0.25M 0.28M
Ebit -41.03600M -33.34400M -14.75000M -16.78200M -13.09500M
Ebitda -40.80000M -33.09400M -14.49500M -16.52800M -12.81300M
Depreciation and amortization 0.24M 0.25M 0.26M 0.25M 0.28M
Non operating income net other 0.24M - 0.02M 0.13M 0.13M
Operating income -40.80000M -33.09400M -14.75000M -16.52800M -12.81300M
Other operating expenses 40.80M 33.09M 14.75M 16.53M 12.81M
Interest expense 1.79M 0.02M 0.07M 0.00000M 0.00000M
Tax provision - - - 0.00000M 0.00000M
Interest income 0.20M 0.02M 0.07M 0.17M 0.17M
Net interest income -1.59000M 0.02M 0.07M 0.17M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.47500M -0.25000M -0.06900M -0.25400M -0.12600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 40.80M 33.09M 14.75M 16.53M 12.81M
Cost of revenue - - - - 0.00000M
Total other income expense net -1.55000M -0.05800M 0.02M 0.13M 0.13M
Discontinued operations - - - - -
Net income from continuing ops -42.35000M -33.15200M -14.73000M -16.39500M -12.68700M
Net income applicable to common shares -42.35000M -33.15200M -14.73000M -16.39500M -12.68700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 19.37M 29.97M 47.52M 40.30M 21.08M
Intangible assets 1.20M 1.42M 1.64M 1.86M 2.09M
Earning assets - - - - -
Other current assets 1.32M 2.45M 1.42M 1.12M 0.67M
Total liab 20.82M 21.67M 19.47M 3.01M 3.03M
Total stockholder equity -1.44800M 8.30M 28.04M 37.29M 18.05M
Deferred long term liab - - - - -
Other current liab 3.47M 3.81M 3.64M 2.51M 1.81M
Common stock 0.09M 0.09M 0.08M 0.08M 0.04M
Capital stock 0.09M 0.09M 0.08M 0.08M 0.04M
Retained earnings -165.75100M -135.93600M -93.58600M -60.43400M -45.70400M
Other liab - - 0.00400M 0.00200M 0.16M
Good will 1.03M 1.03M 1.03M 1.03M 1.03M
Other assets 0.00000M 0.06M 0.18M 0.24M 0.24M
Cash 15.55M 24.77M 43.02M 35.85M 16.66M
Cash and equivalents - - - - -
Total current liabilities 20.81M 5.53M 4.55M 2.94M 2.87M
Current deferred revenue - - - - -
Net debt 1.19M -8.57300M -42.94900M -35.68400M -16.30200M
Short term debt 16.73M 0.06M 0.07M 0.09M 0.20M
Short long term debt 16.66M 16.07M - - -
Short long term debt total 16.73M 16.20M 0.07M 0.17M 0.36M
Other stockholder equity 164.21M 144.15M 121.55M 97.64M 63.71M
Property plant equipment - 0.13M 0.06M 0.04M 0.06M
Total current assets 16.98M 24.84M 44.59M 36.98M 17.38M
Long term investments - - - - -
Net tangible assets - 5.85M 25.37M 34.39M 14.93M
Short term investments - - - - 0.05M
Net receivables 0.11M 0.10M 0.15M - 0.00800M
Long term debt - 16.07M 14.92M - -
Inventory - -2.49300M - - -0.00800M
Accounts payable 0.62M 1.66M 0.84M 0.33M 0.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00400M 0.00400M 0.00400M 0.00400M 0.00400M
Additional paid in capital - - - - -
Common stock total equity - 0.09M - 0.08M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -135.93600M - -60.43400M -45.70400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -1.16800M 2.56M 0.17M 0.24M 0.24M
Deferred long term asset charges - - - - -
Non current assets total 2.39M 5.13M 2.92M 3.32M 3.69M
Capital lease obligations 0.07M 0.13M 0.07M 0.17M 0.36M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M 0.00000M -0.01700M 5.09M -5.08900M
Change to liabilities 0.61M 0.51M 0.10M 0.40M 1.27M
Total cashflows from investing activities - - -0.01700M 5.04M -5.12500M
Net borrowings -0.02000M 14.93M 14.93M 14.93M 14.93M
Total cash from financing activities 19.30M 36.61M 32.68M 17.32M 19.76M
Change to operating activities -0.72000M 0.72M 0.24M -0.98700M 0.99M
Net income -42.35000M -33.15200M -14.73000M -16.39500M -12.68700M
Change in cash -18.25100M 7.17M 19.19M 7.15M 4.01M
Begin period cash flow 43.07M 35.90M 16.71M 9.56M 5.56M
End period cash flow 24.82M 43.07M 35.90M 16.71M 9.56M
Total cash from operating activities -37.54900M -29.44000M -13.47400M -15.21600M -10.62300M
Issuance of capital stock 19.21M 21.34M 29.50M 13.13M 18.43M
Depreciation 0.24M 0.25M 0.26M 0.25M 0.28M
Other cashflows from investing activities - - - 5.09M 0.01000M
Dividends paid - - - - -
Change to inventory - - - - 0.28M
Change to account receivables - - - -0.00100M 0.00200M
Sale purchase of stock 18.03M - 32.68M 4.99M 14.80M
Other cashflows from financing activities 0.08M 15.27M 3.18M 4.20M 1.32M
Change to netincome 3.27M 2.23M 1.29M 1.20M 0.85M
Capital expenditures 0.00000M 0.02M 0.02M 0.05M 0.05M
Change receivables - - - -0.00100M 0.00200M
Cash flows other operating 0.69M - -0.38600M -0.67200M -0.34300M
Exchange rate changes - - - - -
Cash and cash equivalents changes -18.25400M - 19.19M 7.14M 4.01M
Change in working capital 0.10M 1.23M -0.28500M -0.27300M 0.93M
Stock based compensation 3.27M 2.19M 1.29M 1.20M 0.85M
Other non cash items 1.20M 0.04M -19.86000M -0.00300M -7.44400M
Free cash flow -37.54900M -29.45700M -13.49100M -15.26900M -10.66900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ACHV
Achieve Life Sciences Inc		 -0.12 5.69% 1.99 - - - 4.95 -2.4239
NVO
Novo Nordisk A/S		 -4.8 7.63% 58.08 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.79 4.46% 59.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.21 0.66% 489.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 13.88 2.53% 563.16 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Achieve Life Sciences Inc

1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Key Executives

Name Title Year Born
Dr. Richard A. B. Stewart Exec. Chairman 1959
Mr. John A. Bencich M.B.A. CEO & Director 1977
Dr. Cindy Jacobs M.D., Ph.D. Pres, Chief Medical Officer & Director 1958
Mr. Jerry Wan Principal Accounting Officer 1982
Dr. Anthony Clarke Chief Scientific Officer 1956
Ms. Jaime Xinos Exec. VP of Commercial NA
Dr. Richard A. B. Stewart Executive Chairman 1959
Dr. Cindy Jacobs M.D., Ph.D. President, Chief Medical Officer & Director 1958
Ms. Jaime Xinos Executive Vice President of Commercial NA
Mr. Thomas B. King M.B.A. Executive Chairman 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.